Compounds > dmp 323
Page last updated: 2024-08-25

dmp 323 and xv 638

dmp 323 has been researched along with xv 638 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aldrich, PE; Bacheler, LT; Chang, CH; Confalone, PN; Daneker, WF; DeLucca, GV; Emmett, G; Eyermann, CJ; Han, Q; Hodge, CN; Holler, ER; Jadhav, PK; Klabe, RM; Kornhauser, DM; Lam, PY; Li, L; Li, R; Markwalder, JA; McHugh, RJ; Rayner, MM; Ru, Y; Seitz, SP; Sharpe, TR; Shum, L; Winslow, DL1
Akamike, E; Cheatham, WW; Collins, RD; DeLucca, I; Hollis, AY; Lam, PY; Ru, Y; Wilkerson, WW1
Ala, P; Anton, ED; Bacheler, LT; Chang, CH; Garber, SS; Jadhav, PK; Woerner, FJ1
Bacheler, LT; Cordova, B; De Lucca, GV; Erickson-Viitanen, S; Garber, S; Kim, UT; Klabe, RM; Ko, SS; Lam, GN; Liang, J; Logue, KA; Trainor, GL; Wright, MR1
Debnath, AK1

Other Studies

5 other study(ies) available for dmp 323 and xv 638

ArticleYear
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
    Journal of medicinal chemistry, 1996, Aug-30, Volume: 39, Issue:18

    Topics: Animals; HIV Protease Inhibitors; Humans; Molecular Conformation; Structure-Activity Relationship; Urea

1996
HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
    Journal of medicinal chemistry, 1996, Oct-11, Volume: 39, Issue:21

    Topics: Anti-HIV Agents; Benzamides; Chromatography, High Pressure Liquid; HIV Protease Inhibitors; HIV-1; Kinetics; RNA, Viral; Structure-Activity Relationship; Urea; Virus Replication

1996
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Journal of medicinal chemistry, 1997, Jan-17, Volume: 40, Issue:2

    Topics: Amides; Anti-HIV Agents; Cells, Cultured; Crystallography, X-Ray; Drug Resistance, Microbial; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Protein Conformation; Sensitivity and Specificity; Urea

1997
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
    Journal of medicinal chemistry, 1998, Jun-18, Volume: 41, Issue:13

    Topics: Administration, Oral; Animals; Anti-HIV Agents; Azepines; Biological Availability; Cell Line; Chromatography, High Pressure Liquid; Dogs; Drug Design; Drug Resistance, Microbial; HIV Protease Inhibitors; HIV-1; Indazoles; Mutation; Ritonavir; RNA, Viral; Structure-Activity Relationship; Transcription, Genetic; Urea

1998
Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Journal of medicinal chemistry, 1999, Jan-28, Volume: 42, Issue:2

    Topics: Anti-HIV Agents; Crystallography, X-Ray; HIV Protease Inhibitors; Models, Molecular; Structure-Activity Relationship; Urea

1999